Drug Combination Details
General Information of the Combination (ID: C87321) | |||||
---|---|---|---|---|---|
Name | Lycopene NP Info | + | T0901317 Drug Info | ||
Structure | + | ||||
Disease |
Prostate cancer
[ICD-11: 2C82]
|
Investigative | [1] |
Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
---|---|---|---|---|---|---|
α. Enhancing Drug Efficacy by This Combination | ||||||
Achieving Therapeutic Synergy | Click to Show/Hide | |||||
Experiment 1 Reporting the Effect of This Combination | [1] | |||||
Molecule(s)
Regulation |
Up-regulation | Expression | ABCA1 | Molecule Info |
Pathway MAP
|
|
Up-regulation | Expression | NR1H3 | Molecule Info |
Pathway MAP
|
||
Up-regulation | Expression | PPAR-gamma | Molecule Info |
Pathway MAP
|
||
In-vitro Model | DU145 | CVCL_0105 | Prostate carcinoma | Homo sapiens | ||
PC-3 | CVCL_0035 | Prostate carcinoma | Homo sapiens | |||
Experimental
Result(s) |
Lycopene and the LXRalpha agonist T0901317 synergistically inhibit the proliferation of androgen-independent prostate cancer cells via the PPARgamma-LXRalpha-ABCA1 pathway. |